Tag: cancer

Clinical-stage pharma firms Ayala Pharmaceuticals, Advaxis sign merger deal

businessnewstoday- October 22, 2022

Ayala Pharmaceuticals, a Nasdaq-listed clinical-stage oncology company, has entered into a merger deal with New Jersey-based biotech company Advaxis. Based in Delaware, Ayala Pharmaceuticals is ... Read More

Aura Biosciences begins dosing in belzupacap sarotalocan phase 1 trial in NMIBC

businessnewstoday- October 2, 2022

Aura Biosciences said that it has dosed the first patient in a phase 1 clinical trial of its first virus-like drug conjugate (VDC) — belzupacap ... Read More

Dr Reddy’s Labs announces limited volume US launch of Lenalidomide Capsules

businessnewstoday- September 25, 2022

Dr Reddy’s Laboratories said that it has launched two of six strengths of cancer medication Lenalidomide Capsules, a generic of Revlimid, which has been approved ... Read More

Innovent Biologics, Sanofi to expedite development of cancer drugs in China

- August 6, 2022

Chinese biopharma company Innovent Biologics and French pharma giant Sanofi have entered into a partnership that aims to bring innovative drugs to patients in China ... Read More

Amgen to acquire American biopharma company ChemoCentryx for $3.7bn

- August 4, 2022

Amgen has agreed to acquire ChemoCentryx, a biopharma company engaged in developing medications for inflammatory and autoimmune diseases and cancer, in an all-cash deal worth ... Read More

HUTCHMED begins HMPL-A83 phase 1 trial in advanced malignant neoplasms

- July 18, 2022

HUTCHMED (China) has launched a phase 1 clinical trial of its oncology drug candidate HMPL-A83 in China in patients having advanced malignant neoplasms. HMPL-A83 is ... Read More

Merck signs $290m deal with Orion Corporation for mCRPC candidate ODM-208

- July 16, 2022

Merck has signed a global development and commercialization deal worth $290 million with Orion Corporation for the latter’s investigational candidate ODM-208 and other drugs that ... Read More

Prescient Therapeutics gets FDA orphan drug status for PTX-100 in PTCL

- July 15, 2022

Prescient Therapeutics has secured the orphan drug designation for its PTX-100 compound from the US Food and Drug Administration (FDA) for the treatment of peripheral ... Read More

AstraZeneca to acquire US biotech firm TeneoTwo for up to $1.27bn

- July 6, 2022

UK-based pharma giant AstraZeneca has signed a deal worth up to $1.27 billion to acquire American biotech company TeneoTwo in a move to bolster its ... Read More

Ipsen to acquire American biopharma company Epizyme for $247m

- June 27, 2022

French pharma company Ipsen has agreed to acquire Epizyme, a Massachusetts-based commercial-stage biopharma company for an initial consideration of $247 million. Epizyme, which is listed ... Read More